Gonadorelin

Gonadorelin (Synthetic GnRH / LHRH Decapeptide)

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Strong

FDA Approval Scope

Historical FDA approval only: LUTREPULSE (gonadorelin acetate), NDA 019687, was approved on 1989-10-10 and is discontinued. This historical approval does not establish current U.S. commercial availability.

At a Glance

A synthetic version of GnRH — the natural hormone produced by the hypothalamus to regulate the reproductive hormone axis. Historical human evidence includes diagnostic and pulsatile-treatment contexts for hypogonadotropic hypogonadism; it does not establish a current U.S. marketed human product or a general TRT-adjunct use.

Plain English

Researchers study Gonadorelin because it replicates the signal the hypothalamus normally sends to the pituitary to trigger LH and FSH release. Historical studies examined diagnostic and pulsatile-treatment contexts in hypogonadotropic hypogonadism. The historically FDA-approved human LUTREPULSE product is discontinued, and this record does not establish current U.S. commercial availability, routine TRT-adjunct use, or fertility preservation during exogenous testosterone use.

Overview

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a hypothalamic decapeptide that stimulates pituitary LH and FSH secretion. The verified historical literature supports diagnostic and pulsatile-treatment contexts for hypogonadotropic hypogonadism. It does not establish routine twice-weekly TRT-adjunct dosing, fertility preservation during exogenous testosterone use, or a current commercially available U.S. product.

Research Summary

Historical human studies support pulsatile GnRH administration and diagnostic/treatment contexts in hypogonadotropic hypogonadism. This record does not support claims that twice-weekly gonadorelin preserves fertility or testicular function during testosterone therapy, or that it is superior to hCG.

Research Areas

  • Hypogonadotropic hypogonadism
  • Pulsatile GnRH research
  • Reproductive endocrinology

Safety & Risks

Serious Risks

  • Safety is protocol- and route-specific; this record does not establish a current general safety profile.
United States
Historical FDA approval only: LUTREPULSE (gonadorelin acetate), NDA 019687, approved 1989-10-10 and discontinued; this does not establish current U.S. commercial availability.
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources